Neglected Tropical Diseases Diagnosis Market Size & Growth Forecast 2026–2035, By Segments (Diagnostic Method, Service Type, End-use, Disease), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Neglected Tropical Diseases Diagnosis Market size was more than USD 7.12 Billion in 2025 and is set to grow at a 6.2% CAGR between 2026 and 2035, attaining USD 12.99 Billion by 2035. The industry revenue for 2026 is estimated at USD 7.5 billion.

• Base Year Value (2025): USD 7.12 Billion
• CAGR (2026-2035): 6.2%
• Forecast Year Value (2035): USD 12.99 Billion
• Historical Data Period: 2022-2025
• Largest Region: Asia Pacific
• Forecast Period: 2026-2035

Neglected Tropical Diseases Diagnosis Market Intelligence Snapshot:

• Regional Market Dynamics:

  • Asia Pacific held a 33.46% share in 2025, driven by large affected populations and sustained demand for screening, testing, and surveillance.
  • North America is projected to grow at a 7.01% CAGR due to stronger diagnostic preparedness, advanced testing, and increased clinical awareness.

• Segment Momentum:

  • Conventional methods held a 53.55% share in 2025 because they align with existing laboratory infrastructure, workforce expertise, and established testing workflows across diagnostic settings.
  • POC services are the fastest-growing segment as healthcare providers seek faster testing, improved accessibility, and reduced logistical barriers in remote and resource-constrained environments.

• Market Expansion Drivers:

  • Expanding WHO elimination programs and SDG-aligned initiatives accelerating diagnostic deployment.
  • Rising disease burden in low-income regions increasing demand for centralized diagnostic services.
  • Expansion of lab infrastructure and point-of-care diagnostic technology improving detection accessibility.

• Leading Market Participants:

  Prominent companies in the neglected tropical diseases diagnosis market include F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (United States), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Germany), Becton, Dickinson and Company (United States), bioMérieux SA (France), Sysmex Corporation (Japan), Seegene Inc. (South Korea), InBios International, Inc. (United States), Omega Diagnostics Group PLC (United Kingdom).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 7.12 Billion
  • Projected Market Size: USD 12.99 Billion by 2035
  • Growth Forecasts: 6.2% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: Asia Pacific
  • High-Growth Regional Hub: North America
  • Core Revenue Segment: Conventional Method (Diagnostic Method) | Centralized Service (Service Type) | Clinical Labs (End-use) | Dengue (Disease)
  • Emerging Opportunity Segment: Molecular/Modern Method (Diagnostic Method) | POC Service (Service Type) | Home Healthcare (End-use) | Lymphatic Filariasis (Disease)

Market Growth Drivers and Industry Trends

Expanding WHO elimination programs and SDG-aligned initiatives accelerating diagnostic deployment

As WHO-led elimination campaigns and SDG-linked public health agendas move from policy commitments into operational disease control programs, procurement of screening and confirmatory tools becomes a prerequisite for mapping endemicity, identifying treatment-eligible populations, and verifying progress after intervention. This dynamic is supporting market development in the neglected tropical diseases diagnosis market by shifting diagnostics from intermittent donor-supported purchases to planned deployment tied to surveillance rounds, elimination milestones, and reporting requirements. Program managers increasingly rely on standardized diagnostic pathways to target mass drug administration, monitor residual transmission, and document outcomes for funders and health authorities, which supports more consistent demand for assays, test kits, and associated laboratory services.

Rising disease burden in low-income regions increasing demand for centralized diagnostic services

In many low-income settings, a higher caseload of suspected neglected tropical diseases puts pressure on health systems that still lack broad frontline testing capacity, pushing samples and patients toward district hospitals, reference laboratories, and national public health institutes. This is increasing demand for the neglected tropical diseases diagnosis market through greater use of centralized diagnostic services where microscopy, serology, molecular testing, and confirmatory workflows are concentrated. Centralization also reflects practical constraints in endemic regions: clinicians need dependable diagnosis for overlapping febrile, parasitic, and skin-related conditions, while health authorities need aggregated test data to track hotspots and allocate limited treatment resources, reinforcing demand for established laboratory networks and referral-based testing models.

Expansion of lab infrastructure and point-of-care diagnostic technology improving detection accessibility

Investment in laboratory networks and the wider availability of portable, simpler testing formats are changing how suspected cases are identified and confirmed, especially in remote endemic areas where delayed diagnosis has historically limited case finding. In the neglected tropical diseases diagnosis market, this improves market adoption by reducing dependence on distant facilities, shortening turnaround times, and allowing screening to be integrated into outreach programs, primary care visits, and community surveillance. As a result, more individuals are tested earlier in the care pathway, while health systems can expand routine detection beyond specialized campaigns, encouraging market growth for both decentralized point-of-care products and the laboratory platforms that backstop confirmation and quality control.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Expanding WHO elimination programs and SDG-aligned initiatives accelerating diagnostic deployment	2.00%	High	Asia Pacific, Africa	High	Near Term
Rising disease burden in low-income regions increasing demand for centralized diagnostic services	1.70%	High	Latin America, Africa	High	Mid Term
Expansion of lab infrastructure and point-of-care diagnostic technology improving detection accessibility	1.50%	Moderate	Asia Pacific, Latin America	Emerging	Mid Term

Regional Demand Dynamics

Asia Pacific (Largest Region) vs North America (Fastest-Growing Region)

Asia Pacific held a 33.46% share of the neglected tropical diseases diagnosis market in 2025, supported by the region’s large affected population base and the sustained need for broad diagnostic coverage across endemic areas. Market activity is strengthened by the practical demand for screening, confirmatory testing, and disease surveillance in countries where neglected tropical diseases remain a recurring public health burden. This keeps testing volumes elevated across hospital laboratories, public health programs, and outreach-based diagnostic efforts, helping the region maintain its leading position.

North America is projected to expand at a 7.01% CAGR over the forecast period in the neglected tropical diseases diagnosis market, driven by growing attention to imported and travel-associated infections alongside stronger diagnostic preparedness within specialized healthcare settings. Growth is being fueled by wider use of advanced laboratory testing, higher awareness among clinicians, and increased emphasis on early identification in reference labs and research-linked institutions. These dynamics are translating into more consistent testing adoption, particularly where accurate differentiation and timely case detection are operational priorities.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Weak	Moderate	Weak	Moderate	Strong
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	Low	Medium	Low	Medium	Medium
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Global Innovation Hub

The U.S. prioritizes development of advanced diagnostic technologies through collaborations among biotechnology companies, public health agencies, and research institutions. Commercial activity emphasizes rapid, field-compatible testing solutions that support international disease surveillance and global health initiatives.

Japan

Advanced Diagnostic Development

Japan focuses on highly sensitive molecular and immunological diagnostic technologies for neglected tropical diseases. Japanese manufacturers continue refining compact diagnostic systems suitable for clinical and research applications, supporting broader infectious disease preparedness.

South Korea

Rapid Testing Expansion

South Korea is expanding development of rapid diagnostic kits supported by strong biotechnology capabilities. The country's manufacturers are investing in portable and efficient testing solutions that improve accessibility for infectious disease monitoring and international healthcare programs.

Germany

Precision Diagnostics Focus

Germany emphasizes high-quality laboratory diagnostics and validation standards for neglected tropical diseases. The country supports adoption of reliable testing platforms for reference laboratories while encouraging research partnerships that strengthen diagnostic accuracy and regulatory confidence.

France

Public Health Collaboration

France supports neglected tropical disease diagnosis through collaboration between public health organizations, research institutes, and diagnostic developers. The country emphasizes laboratory capacity and surveillance programs that facilitate timely detection and disease management efforts.

Italy

Clinical Laboratory Integration

Italy is strengthening integration of neglected tropical disease diagnostics within hospital and reference laboratory networks. The country's market favors dependable diagnostic workflows that enhance infectious disease identification while supporting collaborative research and public health preparedness.

Segment Leadership and Growth Trends

  Diagnostic Method Segment Analysis: Conventional Method (Largest Segment) vs Molecular/Modern Method (Fastest-Growing Segment)

The Conventional Method segment held the dominant position in the neglected tropical diseases diagnosis market in 2025, accounting for a 53.55% share. Its continued leadership is anchored in routine use across established diagnostic settings, where microscopy, staining, and other conventional approaches remain deeply embedded in laboratory workflows for neglected tropical diseases diagnosis. This segment retains scale because it aligns with existing infrastructure, workforce familiarity, and standard testing practices, making it the most practical option in settings where consistent access and operational continuity matter more than rapid technology transition.

Molecular/Modern Method is the fastest-growing segment in the neglected tropical diseases diagnosis market as healthcare systems increasingly seek greater diagnostic accuracy and earlier detection in complex or low-parasite-burden cases. Its momentum is aided by the practical need to overcome the sensitivity limitations of conventional approaches, particularly where timely identification can improve case management and disease surveillance. Compared with traditional methods, molecular and modern techniques are seeing wider adoption because they better match evolving requirements for precise, scalable, and more reliable diagnostic confirmation.

Service Type Segment Analysis: Centralized Service (Largest Segment) vs POC Service (Fastest-Growing Segment)

In 2025, Centralized Service led the neglected tropical diseases diagnosis market with a 62.93% share. Its dominant position reflects the continued reliance on centralized laboratories and referral-based testing networks for neglected tropical diseases diagnosis, especially where specialized equipment, trained personnel, and quality-controlled processes are required. The segment maintains leadership because centralized models are well suited to handling more complex diagnostic workflows and remain the default structure in many healthcare systems managing infectious disease testing at scale.

POC Service is emerging as the fastest-growing segment in the neglected tropical diseases diagnosis market because it addresses the operational challenge of delivering testing closer to affected populations. Growth is being encouraged by the need for faster clinical decisions in resource-constrained and remote settings, where centralized access can delay diagnosis and follow-up. Relative to centralized pathways, point-of-care services are gaining momentum by improving accessibility and reducing the logistical burden associated with sample transport, making them increasingly relevant for frontline neglected tropical diseases diagnosis.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Diagnostic Method	Conventional Method, Molecular/Modern Method	Conventional Method	Molecular/Modern Method
Service Type	Centralized Service, POC Service	Centralized Service	POC Service
End-use	Clinical Labs, Hospitals /Clinics, Home Healthcare	Clinical Labs	Home Healthcare
Disease	Dengue, Chikungunya, Rabies, Leprosy, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Onchocerciasis, Schistosomiasis, Leishmaniasis, Snakebite Envenoming, Others	Dengue	Lymphatic Filariasis

Competitive Landscape and Market Positioning

Prominent players in the neglected tropical diseases diagnosis market:

1. F. Hoffmann-La Roche Ltd (Switzerland)

2. Abbott Laboratories (United States)

3. Thermo Fisher Scientific Inc. (United States)

4. QIAGEN N.V. (Germany)

5. Becton Dickinson and Company (United States)

6. bioMérieux SA (France)

7. Sysmex Corporation (Japan)

8. Seegene Inc. (South Korea)

9. InBios International Inc. (United States)

10. Omega Diagnostics Group PLC (United Kingdom)

The neglected tropical diseases diagnosis market is experiencing heightened focus on rapid testing technologies, portable diagnostic systems, and affordable disease detection solutions. Market participants are strengthening research collaborations and expanding diagnostic accessibility initiatives to support underserved regions. Advances in molecular diagnostics and point-of-care technologies are contributing to broader market development.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Market Concentration	Low	Fragmented market with diagnostics spread across NGOs, governments, and small biotech firms.
M&A Activity / Consolidation Trend	Low	Limited M&A due to low commercial viability and focus on public health funding.
Degree of Product Differentiation	Medium	Diagnostics vary (e.g., PCR, rapid tests), but overlap in targeting diseases like dengue or leishmaniasis.
Competitive Advantage Sustainability	Unstable	Reliance on grants and inconsistent demand in low-income regions weaken long-term advantages.
Innovation Intensity	Medium	Advances in point-of-care diagnostics and AI-based tools, but constrained by funding.
Customer Loyalty / Stickiness	Weak	End-users (e.g., NGOs, clinics) prioritize cost and availability over brand loyalty.
Vertical Integration Level	Low	Diagnostics developed by specialized firms; distribution relies on global health networks.

Industry Development/News

Company Name	Date	Key Development
GHIT Fund	Oct-25	The Global Health Innovative Technology Fund invested USD 11.6 million into four research and development projects. These initiatives prioritize the advancement of diagnostic tools and vaccines targeting neglected tropical diseases, malaria, and tuberculosis, reinforcing the strategic effort to accelerate innovation in disease control and prevention within underserved global markets.
Bayer AG	Nov-25	Bayer AG and the World Health Organization (WHO) renewed their long-standing partnership to scale up the delivery of free-of-charge treatments for three major neglected tropical diseases. This collaboration optimizes distribution networks in endemic countries, ensuring consistent access to essential therapies and supporting the global strategic objective of eliminating these debilitating conditions.
Sanofi	Sep-24	The World Health Organization approved fexinidazole as an oral treatment for human African trypanosomiasis (sleeping sickness). Developed by Sanofi, this therapy eliminates the need for intravenous administration and hospitalization, representing a transformative shift in clinical practice for remote regions of sub-Saharan Africa and significantly improving the scalability of treatment distribution.
J Mitra & Company	Aug-24	J Mitra & Company launched India's first self-test kit for dengue, targeting early detection via the NS1 antigen from the onset of symptoms. By providing a convenient, point-of-care diagnostic solution, the company is enhancing early intervention capabilities for patients and contributing to more effective outbreak management in high-burden regions.
Drugs & Diagnostics for Tropical Diseases	Oct-23	DDTD, Big Eye Diagnostics, and Medical & Biological Laboratories (MBL) partnered to commercialize a rapid diagnostic test for onchocerciasis. Backed by USD 0.45 million in funding from the GHIT Fund, the test is specifically designed to meet WHO performance requirements, supporting global efforts to control and eliminate the disease through improved field diagnostics.